Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00222820|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : September 22, 2005
We are doing this pilot study to learn more about four aspects of treating depression:
- The features of a depressed person’s mood and anxiety and how these features affect a person’s capacity to get better and stay better.
- If depressed people with certain features of mood and anxiety respond better to therapy, medication or a combination of therapy and medication.
- Whether or not a person’s personality traits affect how they respond to treatment.
- The gene involved in processing antidepressant medication
|Condition or disease||Intervention/treatment||Phase|
|Major Depression||Drug: escitalopram Behavioral: Interpersonal Psychotherapy||Phase 4|
This pilot study is an experimental investigation designed so that consenting subjects are randomly assigned to pharmacotherapeutic or psychotherapeutic interventions for depression.
For the initial phase of treatment, subjects will be randomly assigned to treatment with an SSRI, (escitalopram oxalate or citalopram hydrobromide), or with interpersonal psychotherapy (IPT). Escitalopram will be prescribed for all patients randomized to the medication arm of the study, unless the study psychiatrist determines that citalopram is more clinically appropriate. Escitalopram and citalopram are FDA-Approved SSRI antidepressants indicated for the treatment of depression. In order to optimize outcomes and emulate usual clinical practice, subjects who do not meet response criteria (defined as a 50% reduction in baseline Hamilton Rating Scale for Depression [HRS-D]) or meet stabilization criteria (defined as a mean HRS-D < 7 for 3 weeks) at acute phase Visit 7 or Visit 13 of treatment will have the other treatment added. Subjects who meet stabilization criteria (mean HRS-D < 7 for 3 weeks) at any time between acute phase Visit 13 and 21 will enter the 6-month continuation phase and continue with the treatment that led to their stabilization. Subjects who have not met stabilization criteria by acute phase Visit 21 will remain in active treatment and be offered alternative pharmacotherapy. Subjects who have not responded by acute phase Visit 32 will be discontinued from the protocol and referred for alternative treatment and care.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||35 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Depression: The Search for Treatment-Relevant Phenotypes|
|Study Start Date :||April 2002|
|Study Completion Date :||September 2004|
- Hamilton Rating Scale for Depression
- Inventory of Depressive Symptoms
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00222820
|United States, Pennsylvania|
|Western Psychaitric Institute and Clinic|
|Pittsburgh, Pennsylvania, United States, 15213|
|Principal Investigator:||Ellen Frank, Ph.D.||University of Pittsburgh|